Get started
Immunovant, Inc.Immunovant, Inc.Immunovant, Inc.

Immunovant, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

IMVT trade ideas

IMVT: VCP Pattern / PowerPlaySetup: PowerPlay VCP: 3W 29/7 3T RS: 99 The posted chart contains a VCP (volatility contraction pattern). The first label "W" stands for weekly and shows the duration of the entire consolidation. In the middle label, the percentage of contractions is indicated (for example, "15/4"), with 15 representing the -15% depth of the base and 4 representing -4% of the last contraction. The last part "T" represents the number of contractions. The light blue lines in the chart correspond to the contractions. A more detailed description can be found in Mark Minervini's books. RS stands for relative strength and measures the strength of the stock compared to the overall market. The value range is 1-99 with 99 being the highest value. The rank was generated by fyntrade.
NASDAQ:IMVTLong
by fyntrade
2
Doubled Position $IMVT New Target 26.48 for 52.18% $IMVT Target 26.48 for 52.18% Or next add level is at 8.32 I LOVE a good earnings over-reaction. I doubles my position at 11.87... new target set... — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
NASDAQ:IMVTLong
by SPYder_QQQueen_Trading
3
IMVT is a long swing trade opportunityImmunovant Inc offers at least 75% upside in the $16 range as of March 24, 2021. Weaknesses Stumble in most recent trial for treatment of autoimmune disorder Thyroid Eye Disease (Graves' Ophthalmopathy) General and administrative expenses nearly doubled from $6.10M to $10.50M from Q42019 to Q42020* Net loss of $79.30M for the 9 months ending December 21, 2020, which has nearly doubled compared to the same period in 2019* Obviously fails the "ok boomer" test (see above) and does not pay a dividend Strengths Thyroid Eye Disease affects approximately 16 out of every 100K women yearly in North America and Europe, meaning nearly 27K new cases per year in the US alone Research & Development spend increased by 4X from $5.00M to $21.10M in Q42019 to Q42020 as they expand manufacturing to support clinical trials* Price tumbled almost 45% when Credit Suisse downgraded their IMVT rating from "outperform" to "neutral" and cutting their price target down from $49 to $31 on February 2, 2021 Price hammering continued through the February sell-off to vastly undervalued <$20 range *All financials sourced from Immunovant's December 31, 2020 results published February 16, 2021. TipRank 10 Analysts covering Immunovant including the Credit Suisse Analyst who has further knocked the target price down to $28 Median price target is $38 Chart Price fell far beneath the 200-Day SMA on February 2, 2021 as part of the paused trial 5-Day EMA crossed the 20-Day SMA up on March 15, 2021 and has found support in the $15-$16 range RSI trending <40 since the cross described above Summary Even using the Credit Suisse target of $28, Immunovant Inc has 75% upside based on the current price in the $15-$16 range (and the median $38 price target offers even more potential). IMVT is a swing buy opportunity with conservative initial price target of $28.
NASDAQ:IMVTLong
by danwagnerco
1